Non-alcoholic fatty liver disease and acute cerebrovascular insufficiency — is there a relationship between them?
DOI: 10.32364/2587-6821-2025-9-5-5
V.A. Akhmedov
Omsk State Medical University, Omsk, Russian Federation
Aim: to submit available data on a potential relationship between non-alcoholic fatty liver disease (NAFLD) and acute cerebrovascular disease (ACVD). A correlation between thickness of the intima media of the carotid artery and non-alcoholic steatohepatitis is reported. It was noted that progressive liver fibrosis is significantly associated with a high risk of carotid artery intima-media thickening in patients with NAFLD, and that a history of ischemic ACVD worsens their prognosis. The role of genetic factors (in particular, a PNPLA3 GG genotype) associated with a higher severity of carotid atherosclerosis in young NAFLD patients is highlighted. The author demonstrated that liver fibrosis + steatosis was independently associated with progressive carotid atherosclerosis and an increased risk of ACVD in patients with diabetes mellitus. It was noted that a high FIB-4 index was a significant predictor of recurrent ischemic stroke in males. The data demonstrating NAFLD involvement in occurrence and development of ischemic stroke through intestinal microbiota are submitted. Due to a pathogenetically justified effect, it has been proven necessary to add infusion solutions (in particular, inosine + meglumine + methionine + nicotinamide + succinic acid) protecting the cell membrane from oxidative stress factors in NAFLD therapy. The product significantly reduces clinical and biochemical manifestations of NAFLD. Due to a high risk of endothelial dysfunction and oxidative stress in patients with ACVD + NAFLD, a risk of unfavorable course significantly increases in a poststroke period. This justifies early prescription of neuroprotectors at the first stage of rehabilitation to increase mobilization efficiency in these patients. Inosine + nicotinamide + riboflavin + succinic acid, intravenous solution and enteric-coated tablets, is the only drug of this group included in the clinical guidelines.
Keywords: non-alcoholic fatty liver disease, acute cerebrovascular disease, liver fibrosis, Remaxol, Cytoflavin, inosine, meglumine, methionine, nicotinamide, succinic acid, riboflavin.
For citation: Akhmedov V.A. Non-alcoholic fatty liver disease and acute cerebrovascular insufficiency — is there a relationship between them? Russian Medical Inquiry. 2025;9(5):285–290 (in Russ.). DOI: 10.32364/2587-6821-2025-9-5-5
2. Sun W., Liu D., Yang T. et al. Increased risk of vascular complications in patients with type 2 diabetes and fatty liver disease. BMC Endocr Disord. 2024;24(1):235. DOI: 10.1186/s12902-024-01766-3
3. Xu T., Li S., Wu S. et al. Non-alcoholic fatty liver disease: A new predictor of recurrent ischemic stroke and transient ischemic attack in patients with carotid atherosclerosis. Eur J Radiol. 2024;181:111754. DOI: 10.1016/j.ejrad.2024.111754
4. Gu X., Gao D., Zhou X. et al. Association between fatty liver index and cardiometabolic multimorbidity: evidence from the cross-sectional national health and nutrition examination survey. Front Cardiovasc Med. 2024;11:1433807. DOI: 10.3389/fcvm.2024.1433807
5. Huang W., Wang H., Shen Z. et al. Association between TyG index and risk of carotid atherosclerosis in NAFLD patients: a retrospective cohort study. Front Endocrinol (Lausanne). 2024;15:1448359. DOI: 10.3389/fendo.2024.1448359
6. Eto F., Nezu T., Aoki S. et al. Liver fibrosis index is associated with functional outcome among acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2024;33(2):107537. DOI: 10.1016/j.jstrokecerebrovasdis.2023.107537
7. Chen J., Li X., Hu R. et al. The clinical value of fibrosis indices for predicting the hemorrhagic transformation in patients with acute ischemic stroke after intravenous thrombolysis. Front Aging Neurosci. 2024;16:1492410. DOI: 10.3389/fnagi.2024.1492410
8. Weinstein G., O'Donnell A., Frenzel S. et al. Nonalcoholic fatty liver disease, liver fibrosis, and structural brain imaging: The Cross-Cohort Collaboration. Eur J Neurol. 2024;31(1):e16048. DOI: 10.1111/ene.16048
9. Petta S., Valenti L., Marchesini G. et al. PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One. 2013;8:e74089. DOI: 10.1371/journal.pone.0074089
10. Liao Y.L., Zhu G.Y., Chang C. Non-alcoholic fatty liver disease increases the risk of cardiovascular disease in young adults and children: a systematic review and meta-analysis of cohort studies. Front Cardiovasc Med. 2024;10:1291438. DOI: 10.3389/fcvm.2023.1291438
11. Bisaccia G., Ricci F., Khanji M.Y. et al. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Curr Probl Cardiol. 2023;48(6):101643. DOI: 10.1016/j.cpcardiol.2023.101643
12. Tang A.S.P., Chan K.E., Quek J. et al. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135.602 individuals. Clin Mol Hepatol. 2022;28(3):483–496. DOI: 10.3350/cmh.2021.0406
13. Wang M., Zhou B.G., Zhang Y. et al. Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022;9:812030. DOI: 10.3389/fcvm.2022.812030
14. Malladi N., Alam M.J., Maulik S.K. et al. The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics. Prostaglandins Other Lipid Mediat. 2023;169:106766. DOI: 10.1016/j.prostaglandins.2023.106766
15. Iglesias M.M., Freuer D., Peters A. et al. Association between fatty liver index and blood coagulation markers: a population-based study. Lipids Health Dis. 2023;22(1):83. DOI: 10.1186/s12944-023-01832-1
16. Jose N.P. Vasant P.K., Kulirankal K.G. Study of Endothelial Dysfunction in Patients With Non-alcoholic Fatty Liver Disease. Cureus. 2021;13(12):e20515. DOI: 10.7759/cureus.20515
17. Mori T., Yoshioka K., Tanno Y. Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke. Hepatol Int. 2022;16(1):81–88. DOI: 10.1007/s12072-021-10258-4
18. Fandler-Höfler S., Kneihsl M., Stauber R.E. et al. Liver Fibrosis-4 index indicates atrial fibrillation in acute ischemic stroke. Eur J Neurol. 2022;29(8):2283–2288. DOI: 10.1111/en.15387
19. Kim T.H., Kim S.Y., Jung Y.K. et al. FIB-4 index and liver fibrosis are risk factors for long-term outcomes in atrial fibrillation-related stroke. Clin Neurol Neurosurg. 2022;217:107235. DOI: 10.1016/j.clineuro.2022.107235
20. Bucci T., Nabrdalik K., Baratta F. et al. Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2024;110(1):208–217. DOI: 10.1210/jcem/dgad123
21. Obi M.F., Palmar A.R., Namireddy V. et al. The Liver-Heart Connection: A Literature Review of Liver Disease as a Risk Factor for Atrial Fibrillation. Cureus. 2023;15(5):e38536. DOI: 10.7759/cureus.38536
22. Decoin R., Butruille L., Defrancq T. et al. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation. Front Endocrinol (Lausanne). 2022;13:957245. DOI: 10.3389/fendo.2022.957245
23. Di Stefano C., Milazzo V., Milan A. et al. The role of autonomic dysfunction in cirrhotic patients before and after liver transplantation. Review of the literature. Liver Int. 2016;36:1081–1089. DOI: 10.1111/liv.13089
24. Xiang L., Lou Y., Liu L. et al. Gut microbiotic features aiding the diagnosis of acute ischemic stroke. Front Cell Infect Microbiol. 2020;10:587284. DOI: 10.3389/fcimb.2020.587284
25. Benakis C., Brea D., Caballero S. et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat Med. 2016;22:516–523. DOI: 10.1038/nm.4068
26. Ling Y., Gong T., Zhang J. et al. Gut microbiome signatures are biomarkers for cognitive impairment in patients with ischemic stroke. Front Aging Neurosci. 2020;12:511562. DOI: 10.3389/fnagi.2020.511562
27. Tilg H., Adolph T.E., Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022;34:1700–1718. DOI: 10.1016/j.cmet.2022.11.005
28. Wang H., Zhang M., Li J. et al. Gut microbiota is causally associated with poststroke cognitive impairment through lipopolysaccharide and butyrate. J Neuroinflammation. 2022;19:76. DOI: 10.1186/s12974-022-02441-0
29. Higarza S.G., Arboleya S., Gueimonde M. et al. Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits. PLoS One. 2019;14:e0223019. DOI: 10.1371/journal.pone.0223019
30. Yu G., Chen Q., Chen J. et al. Gut microbiota alterations are associated with functional outcomes in patients of acute ischemic stroke with non-alcoholic fatty liver disease. Front Neurosci. 2023;17:1327499. DOI: 10.3389/fnins.2023.1327499
31. Ng C.H., Xiao J., Chew N.W.S. et al. Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality. Front Med (Lausanne). 2022;9:985803. DOI: 10.3389/fmed.2022.985803
32. Мазина Н.К., Мазин П.В., Суханов Д.С. Клиническая эффективность сукцинатсодержащего инфузионного препарата при фармакотерапии поражений печени различного генеза по результатам мета-анализа. Терапевтический архив. 2013;85(1):56–61.Mazina N.K., Mazin P.V., Sukhanov D.S. The clinical efficacy of a succinate-containing infusion drug during pharmacotherapy for hepatic lesions of varying genesis: results of meta-analysis. Therapeutic Archive. 2013;85(1):56–61 (in Russ.).
33. Стельмах В.В., Козлов В.К. Метаболическая коррекция при дислипидемии у больных с неалкогольной жировой болезнью печени как новая стратегия терапии. Терапевтический архив. 2013;85(4):71–76.Stel'makh V.V., Kozlov V.K. Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy. Therapeutic Archive. 2013;85(4):71–76 (in Russ.).
34. Семисерин В.А., Каракозов А.Г., Малькута М.А. и др. Оценка эффективности гепатопротективной монотерапии неалкогольной жировой болезни печени в стадии стеатогепатита препаратом на основе янтарной кислоты и метионина. Терапевтический архив. 2016;88(2):58–63.Semiserin V.A., Karakozov A.G., Malkuta M.A. et al. Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis. Therapeutic Archive. 2016;88(2):58–63 (in Russ.).
35. Белкин А.А., Алашеев А.М., Белкин В.А. и др. Реабилитация в отделении реанимации и интенсивной терапии (РеабИТ). Методические рекомендации Союза реабилитологов России и Федерации анестезиологов и реаниматологов. Вестник интенсивной терапии имени А.И. Салтанова. 2022;2:7–40. DOI: 10.21320/1818-474X-2022-2-7-40Belkin A.A., Alasheev A.M., Belkin V.A. et al. Rehabilitation in the intensive care unit (RehabICU). Clinical practice recommendations of the national Union of Physical and Rehabilitation Medicine Specialists of Russia and of the national Federation of Anesthesiologists and Reanimatologists. Russian Federation of anesthesiologists and reanimatologists guidelines. Annals of Critical Care. 2022;2:7–40 (in Russ.). DOI: 10.21320/1818-474X-2022-2-7-40
This work is licensed under a Creative Commons «Attribution» 4.0 License.
